AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact
AstraZeneca is paying CSPC Pharmaceutical Group $110 million up entrance to faucet that China-based biotech’s synthetic intelligence-driven expertise for locating ...